Patent ID: 11957687
Assignee: REGENERON PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 5:
6. A compound according to formula (VII):, or a pharmaceutically acceptable salt thereof, wherein:
A is A′, A″, CR4(Ar)2, or Ar;
wherein:, A′ is, A″ is
Z is phenyl, Het, or a C4—C8 cycloalkyl;
Ar is a phenyl, naphthyl, or a C4—C8 cycloalkyl, any of which is optionally substituted with one or more R8 Het; and
Het is a 6-membered heterocycle comprising from 1 to 3 heteroatoms independently selected from N and O, wherein Het is optionally substituted with one or more of C1-3 alkyl, C1-3 alkenyl, halogen, —OH or ═O;
wherein:
when A is phenyl, phenyl is optionally substituted by one or more R7 and not by R8; and
when B is C1-4 alkyl, A is phenyl and R4 is H, then R7 is present and is not —Cl, —F, —CN, C1-4 alkyl, or C1-4 alkoxy;

R4 is H, C1-4 alkyl, or C1-4 haloalkyl;
R6 is independently at each occurrence halogen, —OH, ═O, —CN, —(CH2)0-3—NH2, —(CH2)0-3—NHR#, —(CH2)0-3—N(R#)2, —(CH2)0-3—NHCOOR#, —(CH2)0-3—COOR#, C1-4 alkoxy, C1-12 alkyl, C1-12 alkenyl; C1-4 haloalkyl, C1-4 heteroalkyl with 1 or 2 methylene replaced with —O— or —S—, or C6-12 aryl, any of which is optionally substituted with R*;
j and j′ are indenendently from 0 to 4;
a and b are independently a single bond or a double bonde;
W is ═CH—, ═C(R6)—, —CH2, —CH(R6)—, —(C═O)—, —CH2CH2—, —CH(R6)—CH2—, —O—, —O-13 CH2—, —O—CH(R6)—, —(NH)—, —N(R6)—, —CH2—NH—, —CH2—N(R6)—, or —S—,
wherein:
when W is —CH2—, or when W is —O—CH2—, then A′ is substituted with at least one R6 which is not —OH;

R7 is independently at each occurrence halogen, —CN, ═O, —OH, —(CH2)1-3—OR#, —NH—(C═O)—R*, —NH—(SO2)—R*, —(CH2)1-3—NR#2, —NHR#, —N(R#)2, C1-4 alkoxy, phenoxy, C1-12 alkyl, C1-12 alkenyl, C1-4 haloalkyl, or C6-12 aryl, any of which is optionally substituted with R*;
R8 is independently at each occurrence halogen, —CN, ═O, —OH, —(CH2)0-3—SH, —(CH2)0-3—SR*, —(SO2)—R*, —NH2, —(CH2)1-3—OR#, —NH—(C═O)—R*, —(CH2)1-3—NR#2, —NHR#, or —N(R#)2, C1-4 alkoxy, phenoxy, C1-12 alkyl, C1-12 alkenyl, C1-12 alkynyl, C1-4 haloalkyl, C1-4 haloalkoxy, C6-12 aryl, a 4-7 membered heterocycle with 1 to 4 heteroatoms selected from O, N and S or combinations thereof, or wherein two adjacent R8 groups from a 5-7 membered ring that optionally contains 1 to 3 heteroatoms selected from O, N, and S; any of which is optionally substituted with R*;
R* is halogen, —OH, C1-3 alkyl, C1-3 haloalkyl, phenyl, or benzyl any of which is optionally substitued with a halogen;
R# is C1-3 alkyl, C1-3 haloalkyl, C3-6 cycloalkyl, phenyl, or benzyl, any of which is optionally substituted wiht a halogen;
R5 is independently at each occurrence halogen, —CN, ═O, —OH, —NH2, —(CH2)1-3—OR#, —NH—(C═O)—R*, —NH-13 (C═O)O—R*, —NH—(SO2)—R*, —(CH2)1-3—NR#2, —NHR#, —N(R#)2, C1-4 alkoxy, phenoxy, C1-12 alkyl, C1-12 heteroalkyl comprising 1 to 3 hetero atoms selected from —O—, —S—, or —NH—, C1-12 alkenyl, C1-12 alkynyl, C1-4 haloalkyl, C1-4 haloalkoxy, C6-12 aryl, a 3-7-membered heterocycle with 1 to 4 heteroatoms selected from O, N and S or combinations thereof, or wherein two adjacent R5 groups form a 5-7 membered ring that optionally contains 1 to 3 heteroatoms selected from O, N, and S; any of which is optionally substituted with R*;
k and k′ are independently from 0 to 4;
X is a bond, —CH2—, —CH2—CH2—, —CH2—O—, —CH═CH—, —(C═O)—, —O—, —NR#—, —S—, —(S═O)—, or —(SO2)—; and
B is benzyl or C1-12 alkyl optionally comprising 1-4 O atoms, either of which is optionally substituted by —OH or —OCH.